Your browser is no longer supported. Please, upgrade your browser.
Lexaria Bioscience Corp.
Index- P/E- EPS (ttm)-1.09 Insider Own4.70% Shs Outstand4.05M Perf Week-5.70%
Market Cap25.06M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float2.86M Perf Month-26.38%
Income-3.70M PEG- EPS next Q- Inst Own0.10% Short Float10.32% Perf Quarter4.80%
Sales0.60M P/S41.76 EPS this Y10.30% Inst Trans- Short Ratio1.41 Perf Half Y-13.51%
Book/sh2.90 P/B1.66 EPS next Y- ROA-46.20% Target Price- Perf Year-48.39%
Cash/sh1.88 P/C2.56 EPS next 5Y- ROE-48.90% 52W Range3.98 - 15.64 Perf YTD-35.82%
Dividend- P/FCF- EPS past 5Y-0.60% ROI-163.40% 52W High-69.30% Beta1.68
Dividend %- Quick Ratio27.10 Sales past 5Y92.10% Gross Margin74.80% 52W Low20.75% ATR0.40
Employees4 Current Ratio27.40 Sales Q/Q78.90% Oper. Margin- RSI (14)34.36 Volatility4.89% 7.87%
OptionableNo Debt/Eq0.00 EPS Q/Q127.80% Profit Margin- Rel Volume0.15 Prev Close4.96
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume208.98K Price4.80
Recom1.00 SMA20-11.30% SMA50-21.77% SMA200-34.92% Volume33,096 Change-3.23%
Apr-15-21 04:05PM  
Apr-14-21 07:00AM  
Apr-08-21 08:30AM  
Apr-06-21 07:05AM  
Mar-24-21 07:00AM  
Mar-23-21 07:00AM  
Mar-16-21 07:00AM  
Mar-15-21 07:00AM  
Mar-11-21 07:10AM  
Mar-09-21 08:30AM  
Feb-16-21 06:00AM  
Feb-11-21 07:15AM  
Feb-09-21 08:30AM  
Feb-01-21 06:30AM  
Jan-28-21 10:09AM  
Jan-15-21 03:35PM  
Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.